Lifeward Ltd

Lifeward Ltd (LFWD) Stock Analysis

$5.810

+0.071 (+1.22%)At close

Loading chart…
High
5.964
Open
5.650
VWAP
5.81
Volume
5.03K
Mkt Cap
—
Low
5.650
Amount
29.19K
EV/EBITDA, TTM
-0.85

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.

AI analysis of Lifeward Ltd (LFWD)

Hold

ReWalk Robotics Ltd (LFWD) is not a good buy right now due to its current price of $5.81 being significantly below its 52-week high of $9.61, and the RSI at 45.1 suggests it is neither overbought nor oversold, indicating a lack of strong momentum. Additionally, the company reported a net income loss of $11.5 million in Q2 2026, which raises concerns about its profitability.

Valuation Metrics

The current forward P/E ratio for Lifeward Ltd (LFWD) is 0.00, compared to its 5-year average forward P/E of -2.96.

Forward P/E

Overvalued
5Y Average P/E
-2.96
Current P/E
0.00
Overvalued
-1.37
Undervalued
-4.55

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
-0.08
Current EV/EBITDA
-0.85
Overvalued
0.50
Undervalued
-0.66

Forward P/S

Fair
5Y Average P/S
2.58
Current P/S
0.39
Overvalued
5.94
Undervalued
-0.77

Alphio AI Price Scenarios for LFWD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%LFWD

$1.83

Scenario price

B

Base

Base · 50%LFWD

$1.53

Scenario price

B

Bear

Bear · 25%LFWD

$1.30

Scenario price

Events Timeline

2026-10-01 (ET)

10:00:00

Rewalk Robotics LTD Trading Halted Due to Volatility

2026-08-31 (ET)

16:30:00

Lifeward Appoints Josh Hexter as Interim CEO

2026-08-03 (ET)

09:30:00

Company Not Selling 2.07M Ordinary Shares

2026-05-19 (ET)

08:30:00

Lifeward Appoints Keith Rose as Chief Medical Officer

2026-04-27 (ET)

17:10:00

Lifeward Files to Sell 7.26M Ordinary Shares

News

LFWD FAQ — answered by Alphio AI

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).

ReWalk Robotics Ltd (LFWD) is not a good buy right now due to its current price of $5.81 being significantly below its 52-week high of $9.61, and the RSI at 45.1 suggests it is neither overbought nor oversold, indicating a lack of strong momentum. Additionally, the company reported a net income loss of $11.5 million in Q2 2026, which raises concerns about its profitability.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading